# Jan Wysocki

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 33 papers | 2,951 citations | 257101 24 h-index | 395343 33 g-index |
| 33 all docs | 33 docs citations | 33 times ranked | 3883 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications, 2022, 13, 405. | 5.8 | 92 |
| 2 | A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2022, 33, 1293-1307. | 3.0 | 26 |
| 3 | An update on ACE2 amplification and its therapeutic potential. Acta Physiologica, 2021, 231, e13513. | 1.8 | 33 |
| 4 | A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. Journal of the American Society of Nephrology: JASN, 2021, 32, 795-803. | 3.0 | 82 |
| 5 | Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. Hypertension, 2020, 75, 173-182. | 1.3 | 155 |
| 6 | Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1941-1943. | 3.0 | 95 |
| 7 | The ACE2â€deficient mouse: A model for a cytokine stormâ€driven inflammation. FASEB Journal, 2020, 34, 10505-10515. | 0.2 | 41 |
| 8 | Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. Hypertension, 2020, 76, 1339-1349. | 1.3 | 147 |
| 9 | Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clinical Science, 2020, 134, 543-545. | 1.8 | 369 |
| 10 | ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Clinical Science, 2020, 134, 2791-2805. | 1.8 | 14 |
| 11 | Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiological Reports, 2019, 7, e14242. | 0.7 | 10 |
| 12 | Urinary Renin in Patients and Mice With Diabetic Kidney Disease. Hypertension, 2019, 74, 83-94. | 1.3 | 33 |
| 13 | Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules, 2019, 9, 886. | 1.8 | 39 |
| 14 | Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International, 2018, 94, 114-125. | 2.6 | 94 |
| 15 | Apelinergic system in the kidney: implications for diabetic kidney disease. Physiological Reports, 2018, 6, e13939. | 0.7 | 13 |
| 16 | Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 2017, 95, 473-486. | 1.7 | 40 |
| 17 | Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. American Journal of Physiology - Renal Physiology, 2017, 313, F487-F494. | 1.3 | 32 |
| 18 | A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13. Scientific Reports, 2017, 7, 45473. | 1.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Angiotensin-converting enzyme 2 amplification limitedÂto the circulation does not protect miceÂfromÂdevelopment of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346. | 2.6 | 49 |
| 20 | Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1515-1517. | 2.2 | 11 |
| 21 | Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. American Journal of Hypertension, 2015, 28, 1418-1426. | 1.0 | 28 |
| 22 | Angiotensins and the Heart. Hypertension, 2015, 66, 260-262. | 1.3 | 7 |
| 23 | ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. Physiological Reports, 2014, 2, e00264. | 0.7 | 58 |
| 24 | Angiotensin-Converting Enzyme 2â€“Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators. Hypertension, 2014, 63, 774-782. | 1.3 | 101 |
| 25 | Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. Nephrology Dialysis Transplantation, 2013, 28, 2200-2202. | 0.4 | 14 |
| 26 | Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology - Renal Physiology, 2013, 305, F600-F611. | 1.3 | 60 |
| 27 | Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney International, 2012, 82, 292-303. | 2.6 | 98 |
| 28 | Murine Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2012, 60, 730-740. | 1.3 | 89 |
| 29 | Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney International, 2012, 81, 520-528. | 2.6 | 105 |
| 30 | Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2010, 55, 90-98. | 1.3 | 273 |
| 31 | Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports, 2008, 10, 70-77. | 1.5 | 17 |
| 32 | ACE and ACE2 Activity in Diabetic Mice. Diabetes, 2006, 55, 2132-2139. | 0.3 | 270 |
| 33 | Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes. Journal of the American Society of Nephrology: JASN, 2006, 17, 3067-3075. | 3.0 | 439 |